NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers

NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers

Rivaroxaban is a direct inhibitor of factor Xa, a member of direct oral anticoagulant group of drugs (DOACs). Despite being a widely extended alternative to vitamin K antagonists (i.e., acenocoumarol, warfarin) the interindividual variability of DOACs is significant, and may be related to adverse dr...

Full description

Bibliographic Details
Main Authors: Gonzalo Villapalos-García, Pablo Zubiaur, Dolores Ochoa, Paula Soria-Chacartegui, Marcos Navares-Gómez, Miriam Matas, Gina Mejía-Abril, Ana Casajús-Rey, Diana Campodónico, Manuel Román, Samuel Martín-Vílchez, Carmen Candau-Ramos, Marina Aldama-Martín, Francisco Abad-Santos
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Pharmacogenetics
NAT2
Rivaroxaban
Direct oral anticoagulants
Online Access:http://www.sciencedirect.com/science/article/pii/S075333222300848X

Internet

http://www.sciencedirect.com/science/article/pii/S075333222300848X

Similar Items